Saturday, 20 August 2022
Meet the JournalistsPremiumAucklandWellingtonCanterbury/South Island
CrimePoliticsHealthEducationEnvironment and ClimateNZ Herald FocusData journalismKāhu, Māori ContentPropertyWeather
Small BusinessOpinionPersonal FinanceEconomyBusiness TravelCapital Markets
Politics
Premium SportRugbyCricketRacingNetballBoxingLeagueFootballSuper RugbyAthleticsBasketballMotorsportTennisCyclingGolfAmerican SportsHockeyUFC
NZH Local FocusThe Northern AdvocateThe Northland AgeThe AucklanderWaikato HeraldBay of Plenty TimesHawke's Bay TodayRotorua Daily PostWhanganui ChronicleStratford PressManawatu GuardianKapiti NewsHorowhenua ChronicleTe Awamutu Courier
Covid-19
Te Rito
Te Rito
OneRoof PropertyCommercial Property
Open JusticeVideoPodcastsTechnologyWorldOpinion
SpyTVMoviesBooksMusicCultureSideswipeCompetitions
Fashion & BeautyFood & DrinkRoyalsRelationshipsWellbeingPets & AnimalsVivaCanvasEat WellCompetitionsRestaurants & Menus
New Zealand TravelAustralia TravelInternational Travel
Our Green FutureRuralOneRoof Property
Career AdviceCorporate News
Driven MotoringPhotos
SudokuCodecrackerCrosswordsWordsearchDaily quizzes
Classifieds
KaitaiaWhangareiDargavilleAucklandThamesTaurangaHamiltonWhakataneRotoruaTokoroaTe KuitiTaumarunuiTaupoGisborneNew PlymouthNapierHastingsDannevirkeWhanganuiPalmerston NorthLevinParaparaumuMastertonWellingtonMotuekaNelsonBlenheimWestportReeftonKaikouraGreymouthHokitikaChristchurchAshburtonTimaruWanakaOamaruQueenstownDunedinGoreInvercargill
NZ HeraldThe Northern AdvocateThe Northland AgeThe AucklanderWaikato HeraldBay Of Plenty TimesRotorua Daily PostHawke's Bay TodayWhanganui ChronicleThe Stratford PressManawatu GuardianKapiti NewsHorowhenua ChronicleTe Awamutu CourierVivaEat WellOneRoofDriven MotoringThe CountryPhoto SalesNZ Herald InsightsWatchMeGrabOneiHeart RadioRestaurant Hub

Advertisement

Advertise with NZME.
New Zealand

Covid 19 coronavirus: New Zealanders first to trial Chinese-developed vaccine

23 Jun, 2021 11:20 PM4 minutes to read
There are no new cases of Covid-19 in the community or in MIQ to report.

There are no new cases of Covid-19 in the community or in MIQ to report.

Nikki Preston
By
Nikki Preston

Herald reporter based in Hamilton

VIEW PROFILE

A group of New Zealanders will be the first humans to trial a new second generation covid vaccine out of China.

About 25 young people have this week started being jabbed with the ReCov vaccine as a part of a clinical study.

The trial is being run in partnership with vaccine developer Jiangsu Rec-Biotechnology in China and New Zealand Clinical Research, which has centres in Auckland and Christchurch.

Read More

  • Covid 19 coronavirus: Vaccine for teens to be delivered at schools, parents urged to discuss wi...
  • Covid 19 coronavirus: Medsafe approves Pfizer vaccine for New Zealand 12-15 year olds - NZ Hera...
  • Covid 19 coronavirus - Vaccine 'shortage' frustrations in Bluff: 'We've all sort of sworn a lit...
  • Covid 19 coronavirus: Vaccine hesitancy puts India's gains against virus at risk - NZ Herald
  • Covid 19 coronavirus: MedSafe could approve second vaccine within fortnight - NZ Herald
  • Covid-19 coronavirus: Auckland vaccination invites for those aged over 65 - NZ Herald

NZCR is running the trial which will see 100 people vaccinated with ReCov by September.

Advertisement

Advertise with NZME.

If successful, a larger trial involving thousands of participants would likely also be carried out in New Zealand.

The vaccine will be tested on both a younger population and an older 55 plus population.

NZCR medical director Dr Chris Wynne. Photo / Supplied
NZCR medical director Dr Chris Wynne. Photo / Supplied

NZCR medical director Dr Chris Wynne said they have already started administering a low dose of the vaccine to 25 younger participants.

Once their data was reviewed, the older group would be given the lower dose at the same the younger group got the higher dose. Lastly the higher dose would then be put into the older group.

"We go reasonably slowly. So we dose some people and assess the response and so far there have been no particular issues and we don't expect any, but we are extremely cautious in how we do this according to the protocol."

Wynne said New Zealand was seen as a good place to run a clinical trial because it had a good health system, had a compliant population and could produce high quality research data for the pharmaceutical industry. It was also considered low risk as there was no Covid in the community and there was still a large population who had not been immunised.

He said there was some incredible research coming out of China and the ReCov vaccine and could potentially be better than the current Pfizer vaccine favoured by the NZ Government.

Unlike the Pfizer vaccine, ReCov immunises against two parts of the immune system.

Advertisement

Advertise with NZME.

"So theoretically if there's a mutation in one part of the virus some vaccines will no longer work - the virus may escape the vaccine, but if you've immunised against its two parts you have a much greater chance that the virus will not escape from the immune system."

While the Pfizer vaccine was wonderful and provided immunity to 90 per cent of those who were vaccinated, he said there was a need to be prepared for coronavirus long term and develop more safe and effective vaccines.

Once the current trial showed that it could generate immunity and the vaccine was safe, a much larger second trial would be carried out and it was possible the expanded study could be carried out in New Zealand.

"I would expect that from the animal data, this is likely to be a successful vaccine. So here we will have 100 people who will be successfully immunised."

Other Chinese vaccine makers have conducted human trials in Austria, but this is the first time a Chinese vaccine had been tested in New Zealand.

An American and Asian based company were also in talks with NZCR about running their Covid vaccine studies.

Advertisement

Advertise with NZME.

However, the trials need to be carried out swiftly while the majority of New Zealanders still had not had the Pfizer vaccine, Wynne said.

NZCR is still recruiting participants for the ReCov study and offers just over $3000 in compensation. A large number of participants tended to be students or younger workers.

ReCov has been assessed by a panel of international experts and reviewed by both the New Zealand Health and Disability Ethics Committee and MedSafe.

"I wouldn't do a study that was not in my opinion safe enough for my kids to go in," Wynne said. "There's no higher bar than that."

Advertisement

Advertise with NZME.

Latest from New Zealand

Premium
New Zealand|PoliticsUpdated

Steve Braunias: The secret diary of Gaurav Sharma

19 Aug 06:02 PM
New ZealandUpdated

Firefighters save man trapped on car roof in raging torrent

19 Aug 06:01 PM
Premium
New Zealand

'Due diligence' behind five-year wait to demolish old council headquarters

19 Aug 06:00 PM
Premium
New Zealand

WorkSafe charges Kiwi energy giant over uncontrolled release of scalding steam

19 Aug 05:00 PM
New Zealand

'He is a legend': Cliff Curtis devastated by uncle's death

19 Aug 05:00 PM

Most Popular

Wiggles in NZ: Wiggles star reveals life changing hospital encounter
EntertainmentUpdated

Wiggles in NZ: Wiggles star reveals life changing hospital encounter

19 Aug 06:03 PM
Shamubeel Eaqub on 'stupid' inflation debate and how he'd fix poverty
BusinessUpdated

Shamubeel Eaqub on 'stupid' inflation debate and how he'd fix poverty

19 Aug 06:03 PM
Premium
Steve Braunias: The secret diary of Gaurav Sharma
New Zealand|PoliticsUpdated

Steve Braunias: The secret diary of Gaurav Sharma

19 Aug 06:02 PM

Advertisement

Advertise with NZME.
About NZMEHelp & SupportContact UsSubscribe to NZ HeraldHouse Rules
Manage Your Print SubscriptionNZ Herald E-EditionAdvertise with NZMEBook Your AdPrivacy Policy
Terms of UseCompetition Terms & ConditionsSubscriptions Terms & Conditions
© Copyright 2022 NZME Publishing Limited
TOP